How DexCom (DXCM) Has Traded Around Earnings

What the Historical Beat Rate and Post-Earnings Drift Actually Show

DexCom has beaten earnings estimates in 6 of the last 8 reported quarters, a 75% beat rate, with an average earnings surprise of 5.9%. That track record shows regular upside to the official consensus. The price reaction, however, has not followed in lockstep. Across those same eight quarters, the average 5-day move after earnings was -0.12%, classified as "flat" in the data. Beats have been frequent, but the post-event drift has essentially round-tripped to zero.

The dispersion behind that average is wide. On July 30, 2026, DXCM reported EPS of $0.70 against an estimate of $0.611, a 14.6% surprise, and the stock moved 11.95% the next day. The April 30, 2026 quarter delivered a 20.3% surprise ($0.56 vs $0.4656 estimate) with a 3.02% next-day gain and a 2.28% five-day extension. By contrast, the October 30, 2025 print was a 5.9% beat ($0.61 vs $0.576) yet the stock fell 14.63% the next day and 14.93% over the following five sessions. The February 12, 2026 quarter landed in between: a 4.6% beat produced a 7.59% one-day gain and a 12.29% five-day extension.

Options-Flow Considerations Heading into the October 29, 2026 Report

DXCM's next scheduled earnings release is October 29, 2026 after the market close, with the consensus EPS estimate at $0.67. Options traders focus on implied volatility rather than directional conviction. Given the average 5-day post-earnings drift of -0.12% over the last eight quarters, the straddle market is pricing a binary event where the realized directional edge has historically been negligible.

Recent prints show tail risk runs both ways. While the April 30, 2026 and July 30, 2026 reports produced positive next-day moves, the October 30, 2025 quarter erased 14.63% in one session. For volatility sellers, that skew matters for strike selection. For volatility buyers, it underlines that even an EPS beat does not guarantee a higher stock price at the open. With the stock at $86.58 and RSI at 72.2, option premiums may also reflect broader momentum positioning outside the event itself.

Risk Checklist for the DXCM Earnings Pattern

A disciplined framework separates the earnings outcome from the price reaction. The 75% beat rate and 5.9% average surprise describe earnings consistency; the -0.12% average 5-day drift describes how the market has digested that trend. Traders watch whether the stock is extended relative to its 50-day EMA, which sits at $72.81 versus the current price of $86.58. That gap can amplify sensitivity to any guidance revision or operating metric that diverges from the EPS headline.

Other items include: position sizing for a one-day move comparable to the 11.95% July 2026 gain or the -14.63% October 2025 decline; comparing the implied straddle move to the historical absolute realized moves; and distinguishing between the next-day gap and the five-day drift. Because DXCM falls in the Healthcare/Medical - Devices sector, reimbursement commentary, competitive launches, and gross-margin updates can all move the stock independently of whether the company beats the $0.67 consensus.

For a deeper dive into how institutional analysts and options desks are positioned, see the full institutional verdict on DXCM. Cross-referencing that consensus with these historical reaction metrics can help frame what the market is pricing rather than relying on the headline beat-rate alone.